Adam Koppel
Managing Director @ Bain Capital Life Sciences
Boston, United States
Adam Koppel is a Series A investor at Bain Capital Life Sciences in Boston focused on Health Care and Medical. Adam Koppel, M.D., Ph.D. has served as a member of PTC's board of directors since March 2013.Since November 2003, Adam Koppel has served as a Managing Director of Brookside Capital, the public equity affiliate of Bain Capital. Prior to joining Brookside Capital, he was an Associate Principal with McKinsey & Company where he consulted tocompanies in the pharmaceutical and biotechnology industries.Adam Koppel received an M.D. and Ph.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. from Harvard University.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries Adam Koppel invests in
Stages Adam Koppel invests in
Countries Adam Koppel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (58%)
- Medical 6 (50%)
- Therapeutics 6 (50%)
- Biotechnology 6 (50%)
- Pharmaceutical 2 (17%)
Stage
- Series A 2 (17%)
- Series D 2 (17%)
- Private Equity 2 (17%)
- Seed 1 (8%)
- Series B 1 (8%)
Country
- United States 7 (58%)
- Germany 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
BMS - Autoimmune Disease Drugs Business
|
BMS - Autoimmune Disease Drugs Business develops new therapies for autoimmune diseases. | Series A / Jul 28, 2025 | |
| Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $75M / Series A / Feb 13, 2024 | ||
| Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $109M / Post-IPO Equity / Jan 08, 2024 | ||
| Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $75M / Post-IPO Equity / Sep 30, 2022 | ||
| Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $350M / Series A / Jul 12, 2022 | ||
| Synapticure provides neurodegenerative disease patients with disease specialist and wrap around care, no matter where you live in the US. Founded by patients, we support Dementia, Parkinson's, ALS and more with everyone from on-demand disease-specific neurologists to SLT to 24/7 care coordination and support. | $6M / Seed / Feb 01, 2022 | ||
| ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeuticallyrelevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications. | $80M / Series D / Nov 29, 2018 | ||
| Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stageinvestigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. | $350M / Private Equity / Oct 26, 2018 | ||
| Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. | $70M / Series B / Dec 18, 2017 | ||
| InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany. | $55M / Series D / Oct 13, 2017 | ||
| See all 12 investments → | |||
Co-Investors
Bain Capital Life Sciences specializes in buyouts, inflexion capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enablethat innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflexions in value.
Bain Capital Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Adam Koppel
Managing Director
|
|||
Andrew Hack
Managing Director
|
|||
Benjamin Lund
Partner
|
|||
Coleman Mark
Founder
|
|||
|
Eric Kriss
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Adam Koppel invest in?
Adam Koppel invests primarily in Health Care, Medical and Therapeutics startups, most often at Series A and Series D stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Adam Koppel?
Public channels for Adam Koppel include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Adam Koppel last invest?
The most recent investment recorded for Adam Koppel closed in Jul 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
